Nuformix Achieves Second NXP001 Development Milestone

Cambridge, UK - 15th May 2019

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that in accordance with its updated agreement with NewsummitBiopharma (“NSB”), its licensing partner for China as announced on 27 November 2018, NSB have confirmed a second development milestone for NXP001 has been achieved, triggering a payment of £500,000 to the Company.

Download News

Back to all News